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Identification of cis‑acting 
determinants mediating 
the unconventional secretion of tau
Taxiarchis Katsinelos1,2,3*, William A. McEwan3, Thomas R. Jahn2 & Walter Nickel1
The deposition of tau aggregates throughout the brain is a pathological characteristic within a group 
of neurodegenerative diseases collectively termed tauopathies, which includes Alzheimer’s disease. 
While recent findings suggest the involvement of unconventional secretory pathways driving tau 
into the extracellular space and mediating the propagation of the disease‑associated pathology, 
many of the mechanistic details governing this process remain elusive. In the current study, we 
provide an in‑depth characterization of the unconventional secretory pathway of tau and identify 
novel molecular determinants that are required for this process. Here, using Drosophila models of 
tauopathy, we correlate the hyperphosphorylation and aggregation state of tau with the disease‑
related neurotoxicity. These newly established systems recapitulate all the previously identified 
hallmarks of tau secretion, including the contribution of tau hyperphosphorylation as well as the 
requirement for PI(4,5)P2 triggering the direct translocation of tau. Using a series of cellular assays, 
we demonstrate that both the sulfated proteoglycans on the cell surface and the correct orientation 
of the protein at the inner plasma membrane leaflet are critical determinants of this process. Finally, 
we identify two cysteine residues within the microtubule binding repeat domain as novel cis‑elements 
that are important for both unconventional secretion and trans‑cellular propagation of tau.
A major pathological feature of several neurodegenerative diseases, including Alzheimer’s disease (AD), is the 
accumulation of hyperphosphorylated and detergent-insoluble tau  assemblies1. Physiologically, tau stabilizes 
and promotes the assembly of  microtubules2, a function mediated by the microtubule binding repeat domain 
(MTBR) and its flanking regions at the C-terminus2,3. However, under pathological conditions tau becomes 
extensively phosphorylated at epitopes normally unaffected in healthy  individuals4,5. These series of modifica-
tions subsequently lead to its detachment from microtubules and contribute to the formation of intracellular 
aggregates, such as neurofibrillary tangles and paired helical filaments in  AD6.
An important aspect in the development of the pathology is that the deposition of tau aggregates through-
out the brain follows a stereotypic pattern, which directly correlates the affected regions with the occurring 
 symptoms7,8. Moreover, the increased levels of extracellular tau in the cerebrospinal fluid (CSF) is a commonly 
used biomarker for diagnosis and staging of the disease, as they typically precede the onset of  symptoms9,10. 
Therefore, over recent years the emerging hypothesis in the field includes the trans-cellular spreading of aggre-
gated tau species, where pathological species spread from affected brain areas to healthy neuronal clusters and 
convert naïve tau to the pathological  form11. Such processes have been experimentally reproduced in vivo and in 
cellulo through the administration of recombinant or ex vivo-derived fibrils, where in both cases the endogenous 
tau was effectively seeded into insoluble  aggregates12–15.
We and others have demonstrated that the release of tau molecules from cells occurs via active cellular 
mechanisms that significantly impact the propagation of pathological  conformations16–18. This set of protein 
externalization mechanisms are collectively termed Unconventional Protein Secretion (UPS) and the common 
feature within proteins following such routes is that their export to the exterior does not rely on the classical 
secretory  pathway19. Initial reports proposed tau secretion to occur through a Type III UPS pathway mediated 
by  exosomes19–21. However, the levels of tau associated with these vesicles are rather low when compared to the 
free tau protein, which represents about 90% of extracellular  tau22,23. Recently, evidence for unconventional 
secretion of tau through a Type I UPS pathway has been  reported16,17, a mechanism that is based on direct 
protein translocation across the plasma  membrane19,24. More specifically in this process, the disease-associated 
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hyperphosphorylation of tau reduces its affinity to the microtubules, leading to increased levels of intracellular 
protein available for  secretion16,25. Subsequently, free cytosolic tau is recruited at the inner plasma membrane 
leaflet through its interaction with PI(4,5)P216 as well as with other lipidic components, such as cholesterol and 
 sphingomyelin17. Finally, the translocation process is completed by sulfated proteoglycans (PGs) on the outer 
cell surface, which act as anchor points that retain the majority of the extracellular tau  population16,26.
This mechanism shares striking similarities with the secretory route of fibroblast growth factor 2 
(FGF2), a leaderless signalling protein with significant endocrine and autocrine functions in development 
and  tumorigenesis19,24. The efficient secretion of FGF2 is initiated by the docking of the protein to the  Na+, 
 K+-ATPase27 and the subsequent interaction with PI(4,5)P2 at the inner leaflet of the plasma  membrane28–30. 
These two cellular components alongside Tec  kinase31 and heparan sulfate proteoglycans (HSPGs)32,33 comprise 
the trans-elements that mediate unconventional secretion of FGF2. Concomitantly, the cis-elements include the 
positively charged epitopes of FGF2 mediating the interaction with  Na+,  K+-ATPase (K54 and K60)34, PI(4,5)
P2 and HSPGs (K127, R128, and K133)29 as well as the phosphorylation target of Tec kinase (Y81)31. This set is 
completed with the two surface cysteine residues (C77 and C95) that foster the assembly of membrane-spanning 
FGF2-oligomers through the formation of intermolecular disulfide  bridges35. Intriguingly, depending on the 
isoform type derived from the alternative mRNA splicing of exon 10, there are up to two cysteine residues in the 
amino acid sequence of tau (C291 and C322)36. As previous studies suggest that these residues are implicated in 
the formation of oligomeric species via inter- and intra-molecular disulfide  bonds37, we questioned their potential 
contribution to the secretion of tau from cells.
In the current study, using in vivo and in cellulo systems, we correlate the phosphorylation status of tau with 
its aggregation propensity and the associated toxicity. Moreover, we demonstrate that secretion of tau to the 
extracellular space follows an active route, which is not significantly influenced by cell death, but requires the 
functional orientation of the protein at the inner plasma membrane leaflet for its successful translocation into 
the extracellular space. Most importantly, we identify a novel cis-element, namely the two cysteines within the 
MTBR that govern the unconventional secretion and trans-cellular propagation of tau to adjacent cells.
Results
Phosphorylation of tau determines its toxicity and secretion in Drosophila melanogaster mod-
els. The expression of human tau leads to a robust reduction in the lifespan of Drosophila melanogaster, which 
is further exacerbated by disease-associated  mutations38,39. In order to delineate the impact of aggregation and 
phosphorylation on the in vivo-induced toxicity, we employed wild type (wt) human 0N4R tau and two variants 
bearing mutations in 14 commonly phosphorylated serine/threonine (S/T)  residues40,41. In one construct, those 
S/T residues have been mutated to glutamate (E14) thereby mimicking the phosphorylated state. Alternatively, 
mutation of these S/T residues to alanine (AP) lead to complete impairment of phosphorylation at these sites. As 
the pan-neuronal expression of tau E14 under the elav-Gal4 driver was severely toxic in our experiments dur-
ing the developmental stages, we used a driver line for targeted integration and thereby equal expression of the 
different tau variants in neuronal and non-neuronal post-mitotic cells of the retinal tissue (GMR-Gal4, Fig. 1a). 
The major advantage of this system is that the eye-related toxicity does not affect animal  viability42 and indeed we 
observed no impairment in the lifespan of these transgenic flies. In line with previous  observations43, mutation 
of these S/T epitopes to a phosphomimetic state (E14) led to significantly enhanced toxicity compared to the AP 
variant or the control line expressing GFP (Fig. 1b,c). Biochemical analysis of these flies demonstrated that the 
tau E14 variant was substantially enriched in the Sarkosyl-insoluble fraction (Fig. 1d), suggesting that the pres-
ence of aggregated species contributes to the in vivo toxicity.
To allow a detailed analysis of the relationship between tau phosphorylation, aggregation and secretion pro-
pensity in a closely related experimental setup, we employed a neuronal cell culture line derived from the central 
nervous system of the fruit fly (BG2-c6)44 and ectopically expressed the aforementioned human tau variants. 
Initially, we assessed the expression characteristics of the wt variant in these cells under the metallothionein 
inducible  promoter45. We biochemically confirmed that a C-terminally tagged version of tau with three repeats 
of hemagglutinin peptide (3xHA) was efficiently phosphorylated by endogenous kinases (Fig. S1a), indicating 
the functionality of human tau in the Drosophila neuronal cells. We next determined the  Cu2+ concentrations 
and timings that allowed us to obtain optimal tau expression levels (Fig. S1b, c). Even though the intracellular 
accumulation of tau wt plateaued at about 60 h upon addition of  Cu2+ (Fig. S1c), its phosphorylation was already 
apparent even at the earliest time points (Fig. S1d).
Having established this novel cell culture setup, we expressed and characterized wild-type tau alongside the 
two phospho-tau variants, E14 and AP. All constructs accumulated over time in the soluble fraction, with the 
tau E14 forming higher levels of Sarkosyl-insoluble aggregates compared to tau wt and tau AP (Fig. 2a). We 
also noted that the introduced mutations as well as the phosphorylation modifications led to characteristically 
distinct mobility in SDS-PAGE (Fig. 2a). Interestingly, the expressed tau AP variant in the Drosophila neuronal 
cells displayed two distinct protein bands, with only the lower molecular weight species being detected in the 
insoluble fraction (Fig. 2a). The difference in the SDS-PAGE mobility between these two bands was a result of 
differential phosphorylation by endogenous kinases, which we determined by in vitro dephosphorylation experi-
ments (Fig. 2b). Moreover, our detailed phospho-mass spectrometry mapping (Fig. S1e, Supplementary Tables S1, 
S2, and S3) identified 4 residues that are exclusively phosphorylated in the high (high P-band, marked with an 
asterisk in Fig. 2a,b, and Fig. S1e), but not in the lower molecular weight versions of the tau AP variant (low 
P-band, marked with an arrow in Fig. 2a,b, and Fig. S1e). Nevertheless, all the tested tau variants demonstrated 
the expected cellular association with the cytoskeleton and more specifically at the microtubules (Fig. 2c), while 
in contrast to the in vivo data (Fig. 1a) none of them caused any apparent toxicity to the cells (Fig. 2d). As we 
have previously shown that phosphorylation acts as a pivotal driver of tau  secretion16, we addressed this property 
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in our new cell culture system. Having determined the optimal immunoprecipitation conditions to enrich for 
tau from the medium of the Drosophila neuronal cells (Fig. S1f), we tested the culture supernatants for the pres-
ence of each variant in different time points. Interestingly, the phosphorylation status of the tested tau variants 
correlated well with their secretion propensity, meaning that the phosphomimetic tau E14 was secreted already 
at 48 h post induction, whereas the wt and the AP variants were barely detectable even after 72 h of expression 
(Fig. 2e). These findings demonstrate the intrinsic property of hyperphosphorylated tau to be secreted to the 
extracellular space from a wide range of experimental models and further supports the suitability of our system 
for a more detailed analysis of the involved elements.
Tau is actively secreted via type I UPS mechanisms as a free soluble protein. To further address 
the secretion specificity of the phosphomimetic tau E14, we employed as an additional control a different micro-
tubule-associated protein, namely the Tubulin Polymerization-promoting  Protein46 (TPPP, Fig. 3a). Even though 
both proteins demonstrated a similar tubulin localization profile upon expression in Drosophila neuronal cells 
(Fig. 3a), TPPP was barely detectable in the conditioned medium (Fig. 3b), with levels similar to these of tau wt 
and significantly lower than those of tau E14 (Fig. 3c). Moreover, we investigated the dependence of tau secretion 
on temperature as an additional criterion for active secretion mechanisms. For this, the Drosophila neuronal cells 
expressing the phosphomimetic tau were incubated with fresh medium at 25 °C or 4 °C for 6 h. As expected, we 
observed a small reduction of the intracellular tau after this short treatment (Fig. 3d). However, this change in 
culturing conditions led to a significant reduction of the extracellular tau levels by approximately 60% (Fig. 3d 
and Fig. S2a), suggesting the specificity of tau secretion as an active cellular process.
Subsequently, we questioned the potential contribution of the canonical secretory pathway using two specific 
inhibitors, namely Brefeldin A and Monensin. The efficacy of those compounds was assessed by treating cells 
expressing a tau E14 version that was re-directed to the ER/Golgi upon fusing the signal peptide sequence of 
the Drosophila Larval Cuticle Protein 1 (LCP1)47 at the N-terminus of tau E14 (SP-tau E14, Fig. S2b). While 
the treatment with Brefeldin A and Monensin effectively reduced the secretion of the SP-tagged version, none 
of them had any influence on the cellular localization and secretion of tau E14 (Fig. 3e, Fig. S2b and c). Finally, 
Figure 1.  Tau hyperphosphorylation induces toxicity to Drosophila melanogaster upon expression in the retina. 
(a) Schematic illustration of the experimental setup and the parameters used to assess the toxicity in Drosophila 
retinal cells. (b) Representative images from Drosophila melanogaster eye phenotypes upon expression of 
different constructs under the GMR-Gal4 promoter element. (c) The severity of roughness in the eye phenotype 
was quantified using the Flynotyper ImageJ-based plugin and then normalized to the GFP control. Bars 
represent mean values ± s.d., n ≥ 6 animals/genotype were assessed. (d) Sarkosyl-soluble and insoluble fractions 
were isolated from transgenic Drosophila melanogaster brain homogenates and blotted against pan-tau and GFP, 
while actin was used as loading and assay quality control.
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Figure 2.  Phosphomimetic tau is preferentially secreted from Drosophila neuronal cells. (a) Sarkosyl-
soluble and insoluble fractions from cells expressing the different tau variants were isolated and subsequently 
blotted against HA and actin. Asterisk and arrow indications correspond to the P- and non-P band of tau AP, 
respectively. (b) Lysates from transfected cells were subjected to dephosphorylation and then immunoblotted 
against HA. Actin was used as loading control. Asterisk and arrow indications correspond to the P- and 
non-P band of tau AP, respectively. (c) Antibodies against HA and tubulin were used to stain tau and tubulin, 
respectively, whereas the nucleus was stained with Hoechst (scale bar, 15 µm). (d) Conditioned media from 
cells expressing the different tau variants or the empty vector were collected and tested for levels of cell death, as 
determined by the release of LDH. Data represent mean values ± s.d., n = 3 biological replicates. (e) Lysates and 
immunoprecipitated medium from cells expressing the different tau variants were immunoblotted against HA 
for detection of tau and actin as loading and quality control. Asterisk and arrow indications correspond to the 
P- and non-P band of tau AP, respectively.
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we examined the contribution of the Type III UPS pathway on the secretion of tau E14 in our newly developed 
Drosophila neuronal culture system, as tau secretion has been associated with such  vesicles23. The successful 
isolation of these fractions from the conditioned media was validated through the employment of the exosome-
associated Tsp96F  protein48 (Fig. 3f and Fig. S2d). We were able to detect only minor amounts of insoluble or 
exosome-associated extracellular tau E14, while the vast majority was retained as free and non-vesicle associated 
protein (Fig. 3f). Taken together, these data demonstrate that active Type I secretory mechanisms mediate the 
direct translocation of phosphorylated tau across the plasma membrane as a free and soluble protein.
Translocation to the extracellular space relies on freely‑diffusing cytoplasmic pools of tau. We 
and others have previously demonstrated that the sulfated proteoglycans (PGs) are not only essential for the 
uptake of  tau49, but they are also critically involved in the Type I secretion of tau to the  exterior16,17. To address 
their contribution on the secretion of tau from Drosophila cells, we subjected them to increasing concentrations 
of sodium chlorate  (NaClO3), a molecule that blocks the last sulfation step of all  PGs50. Even though the treat-
ment with  NaClO3 did not affect the intracellular levels of tau (Fig. 4a), the recovered amount from the condi-
tioned medium demonstrated a dose-dependent reduction, which was already significant at a concentration of 
25 mM (Fig. 4a,b). Notably, the surface-retained portion of tau E14, which was retrieved through heparin wash 
of living cells, was only mildly affected at the same concentration, but displayed a greater decrease (approxi-
mately 50%) upon treatment with 50 mM  NaClO3 (Fig. 4a,c).
Furthermore, the interaction of tau with the inner plasma membrane leaflet has been suggested to represent 
an important factor for the efficient translocation of the protein to the extracellular  space16,17. Taking this into 
consideration, we hypothesized that redirecting tau to distant cellular compartments would inhibit its release 
from cells, whereas the redirection to the plasma membrane could potentially enhance its secretion. To address 
Figure 3.  Phosphomimetic tau is secreted as a free protein via UPS Type I mechanisms. (a) Cells expressing 
tau E14 and TPPP were stained using HA antibody, while Hoechst dye was employed for the nucleus (scale bar, 
15 µm). (b,c) Lysates and immunoprecipitated media were blotted against HA and Glo1. The densitometrically 
quantified secreted levels were initially normalized to the cell lysates and subsequently compared to tau E14. 
The data represent mean values ± s.d. derived from at least 3 biological replicates and were subjected to one-way 
ANOVA, followed by Tukey’s post hoc test. (d) Cell lysates and immunoprecipitated media from cells cultured 
for 6 h at normal conditions (25 °C) or at 4 °C were immunoblotted against HA and Glo1. (e) Lysates and 
immunoprecipitated medium from treated and untreated cells were immunoblotted against HA and actin. (f) 
Sarkosyl-insoluble and exosomal-associated proteins were isolated from conditioned media, while soluble and 
vesicle-free fractions were subjected to immunoprecipitation. All fractions were immunoblotted against HA, 
while Glo1 was used as loading and quality control.
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this, we generated artificial tau E14 constructs that re-routed the protein to the nucleus or the plasma membrane 
through nuclear localization (NLS) or plasma membrane targeting  signals51, respectively (Fig. 4d). The latter was 
initially attempted through fusing the C-terminal signal of the K-Ras4B52 to tau E14, but the chimeric protein 
was poorly expressed (Fig. 4e), potentially due to stability issues. This problem was bypassed by employing the 
N-terminal sequence of the tyrosine kinase Lck protein, which drives plasma membrane targeting through lipid 
modifications, such as palmitoylation, myristoylation and S-acylation53,54. As expected, forcing the protein to 
localize in the nucleus significantly impaired the secretion efficiency of tau E14 (Fig. 4e,f). Intriguingly though, 
the re-direction of tau to the plasma membrane via the Lck-targeting signal also led to reduced levels of secreted 
protein (Fig. 4e,f). Taken together these findings indicate that the enforcement of tau to dock at the plasma 
membrane is not sufficient to promote its secretion to the extracellular space and suggest that the translocation 
process relies on the diffusion of the tau protein in the cytoplasm to allow the interaction with the PI(4,5)P2 at 
inner leaflet of the plasma membrane.
Figure 4.  Type I unconventional secretion of tau depends on the presence of functional sulfated proteoglycans. 
(a) Tau E14-expressing cells were treated with increasing concentrations of  NaClO3 and upon collection of 
the conditioned media, the living cells were incubated with Heparin to retrieve the surface-bound proteins 
prior to cell lysis. Both medium and Heparin fractions were subjected to immunoprecipitation and were 
immunoblotted together with lysates against HA and actin. (b,c) Secreted and surface-associated fractions 
were densitometrically quantified, normalized to the intracellular levels, and then compared to the untreated 
control. The data represent mean values ± s.d. derived from n = 7 biological replicates for the medium and n = 5 
for the Heparin data. Statistical analysis was performed through one-way ANOVA and followed by Tukey’s 
post hoc test. (d) Cells expressing tau E14 with and without cellular localization signals were stained against 
HA and tubulin, whereas Hoechst was used for nuclear staining (scale bar, 15 µm). (e,f) Cell lysates and 
immunoprecipitated media from cells expressing the tau E14 variants were immunoblotted against HA and 
Glo1. The densitometrically quantified secreted tau was initially normalized to the intracellular levels and then 
compared to the original tau E14 variant. The data represent mean values ± s.d. derived from at least 3 biological 
replicates and were subjected to one-way ANOVA, followed by Tukey’s post hoc test.
7
Vol.:(0123456789)
Scientific Reports |        (2021) 11:12946  | https://doi.org/10.1038/s41598-021-92433-3
www.nature.com/scientificreports/
The two cysteines of tau are a critical cis‑element in its unconventional secretion path-
way. The interaction of proteins with the plasma membrane is a critical step in the translocation process 
within the Type I  UPS16,29,55. The most well-characterized representative is FGF2, where the two surface cysteines 
(C77 and C95) govern the efficient secretion of the protein through the formation of membrane-inserted inter-
molecular disulfide  bridges35. Intriguingly, depending on the resulted isoform due to the alternative splicing of 
the second repeat, tau may also contain up to two cysteines (C291 and C322, Fig. S2e) that have been associ-
ated with the formation of intra- or intermolecular disulfide bonds. To address the impact of these two residues 
on the secretion propensity of tau we generated two mutant versions of tau E14 by mutating the first cysteine 
(tau E14 C291A) or both cysteine residues to alanine (tau E14 C291A/322A, Fig. S2e), thereby either allowing 
exclusively the formation of intermolecular disulfide bridges or completely blocking them, respectively. Even 
though the expression levels were similar among the different tau E14 variants (Fig. 5a), the secretion efficiency 
of both the single and the double-cysteine mutant variants was almost half compared to the one with all avail-
able cysteines (Fig. 5a,b). Most intriguingly, we observed no significant differences in the secreted levels between 
the single and the double cysteine tau E14, indicating that the presence of one cysteine and therefore the for-
mation of intermolecular disulphide bridges between tau molecules is not sufficient to mediate tau secretion. 
Aiming to validate these findings, we generated stable cell lines in our previously established CHO cell culture 
 system16. Similar to the results obtained from the Drosophila neuronal cells, the cellular localization of the dou-
ble cysteine-mutant variant was indistinguishable from tau E14 (Fig. 5c) and the expression levels between them 
were also comparable (Fig. 5d). However, the secreted levels of tau E14 C291/322A in the culture medium were 
reduced by approximately 50% when compared to that of tau E14 (Fig. 5d,e). In line with the observations in the 
Drosophila neuronal cells, mutation of cysteine-291 to alanine also resulted in a stark reduction of the tau E14 
in the culture medium, but without any significant difference compared to the double-cysteine mutant (Fig. S3a 
and b). Additionally, the surface-retained population of the double-cysteine mutant tau E14 as determined by 
surface biotinylation experiments on living cells was even further reduced by 65% (Fig. 5d,f). As the sulfated PGs 
represent an important factor in the secretion of tau (Fig. 4a–c), we analysed whether our newly developed CHO 
double-cysteine tau E14 cell line has altered levels of sulfated PGs. However, both the levels and the distribu-
tion of cell surface-associated sulfated PGs was indistinguishable between the tau E14 and tau E14 C291/322A 
cells (Fig. S3c). These findings demonstrate that the reduced Type I UPS secretion of tau in the cysteine mutant 
variants is solely attributed to these residues and underlines the importance of this novel cis-element in the 
translocation process.
Cell‑to‑cell spreading of tau relies on the availability of cysteines. The spread of tau pathology 
relies on the induction of seeded tau aggregation upon trans-cellular propagation in naïve  cells56. Having dem-
onstrated the significance of the two cysteines of tau in its unconventional secretory mechanism, we tackled the 
impact of these mutations on the trans-cellular spreading and induction of aggregation in adjacent cells. The first 
aspect was addressed through co-culturing combinations using our previously established CHO tau cell-to-cell 
spreading  assay16. More specifically, in this experimental setup the tau expressing cells (donor line) were co-
cultured with cells expressing FGF2-GFP (acceptor line) and we actively searched for tau positive signal inside 
the acceptor cells as indication of trans-cellular spreading events. In accordance with the secretion phenotypes, 
the spreading events were easily detectable for tau E14, while the occurrence of tau positive signal inside the 
acceptor cells was less abundant when the double-cysteine mutant version was employed (Fig. 6a). Levels were 
quantified through an image-based analysis, where we also employed a control cell line deficient for three out of 
four sulfated PGs  (CHO745) and thereby impaired tau trans-cellular spreading  efficiency16,57. In depth-analysis of 
these combinations demonstrated that the spreading propensity of the tau E14 C291/322A mutant was almost 
half of the tau E14 (Fig. 6b), a reduction that is in accordance with the 50% lower extracellular tau levels obtained 
from these cells.
We next investigated the ability of tau E14 C291/322A to induce aggregation upon trans-cellular spreading 
to adjacent cells. We employed our CHO-based aggregation biosensor cell line expressing the repeat domain 
of tau fused with GFP (RD-GFP)16. Similar systems have been reported for their high sensitivity in detecting 
aggregation upon certain stimuli, such as the exogenous administration of recombinant or patient-derived 
 aggregates14. Indeed, the liposome-mediated transduction with recombinant filaments efficiently induced the 
aggregation of the expressed RD-GFP (Fig. S3d and e). In agreement to the cell-to-cell spreading data, the cells 
expressing the phosphomimetic tau were able to induce the aggregation of RD-GFP in co-culturing conditions 
(Fig. 6c). However, neither the double-cysteine tau E14 mutant  (CHOK1 tau E14 C291/322A) nor the sulfated 
PGs-deficient tau E14 donor cell line  (CHO745 tau E14) led to such phenotypes (Fig. 6c,d). Taken together, these 
observations further emphasize the significance of the Type I UPS pathway tau is making use of during trans-
cellular propagation and identify the two cysteines residues in tau as a novel cis-element required for this pathway.
Discussion
Over the recent decades the trans-cellular propagation of pathological tau conformations has gained traction as a 
driver of disease pathogenesis in AD. This has been supported by the increasing evidence associating the elevated 
levels of tau in the  CSF9 with the stereotypic deposition of misfolded tau species throughout the brain during 
disease  progression7. The proposed mechanisms involve the release of hyperphosphorylated tau species from 
affected neurons and their uptake from healthy cells, where they seed naïve tau molecules and thereby transmit 
the aggregated  state11. The significance of such seeded-templated aggregation events are further highlighted by 
the structural differences between the endpoint tau amyloid conformations in neurodegenerative diseases, which 
might in turn define the phenotypic discrepancies between  tauopathies58–60.
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In the current study, we demonstrate a direct link between phosphorylation, de novo aggregation and its 
associated neurotoxicity in tau pathology. The hyperphosphorylation of tau has been extensively linked to 
 neurodegeneration6 and our findings further support this notion, as both the phosphomimetic and the phos-
phorylated wild-type tau variants induce severe roughness in the fly eye. These toxic phenotypes in the fruit fly 
have been previously attributed to pathological cell-cycle activation of TOR-mediated  pathways41 and impaired 
axonal  transport61 deriving from soluble cytosolic tau  species43. However, in accordance with other in vivo 
Figure 5.  Cysteines in tau are a critical cis-element for its efficient secretion. (a,b) Conditioned media from 
Drosophila neuronal cells expressing either tau E14 and the corresponding single or double-cysteine mutant 
version (C291A and C291/322A, respectively). were immunoprecipitated and together with the cell lysates 
samples were immunoblotted against HA and Glo1. The secreted amounts were densitometrically quantified, 
normalized to the intracellular levels and then compared to the tau E14 levels. The data represent mean 
values ± s.d. derived from n = 10 biological replicates and were subjected to unpaired t test that was followed 
by Welch’s correction. (c)  CHOK1 cells expressing tau E14 or E14 C291/322A were fixed and stained for tau, 
tubulin, and nucleus using antibodies against HA, tubulin, and the Hoechst dye respectively (scale bar, 15 µm). 
(d) The conditioned medium from  CHOK1 cells expressing tau E14 or tau E14 C291/322A was subjected to 
immunoprecipitation, while cell surface biotinylation was performed on living cells to isolate the cell lysates 
(C) and the surface-associated (S) fractions. All samples were immunoblotted against HA for the detection of 
tau, while GAPDH was used as loading, cell integrity, and assay quality control. (e,f) The densitometrically 
quantified secreted amounts in the medium were initially normalized to the expression levels and subsequently 
compared to tau E14, while the surface-associated fractions were compared to the total expression levels. In both 
cases, the data represent mean values ± s.d. derived from n = 8 and 4 biological replicates, respectively. Statistical 
analysis was performed via unpaired t test, which was followed by Welch’s correction.
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Figure 6.  The availability of cysteines drastically influences the trans-propagation of tau. (a)  CHOK1 cells 
expressing either tau E14 or tau E14 C291/322A were co-cultured with FGF2-GFP cells for 48 h and were 
subsequently stained for tau, FGF2, and nucleus using antibodies against HA, GFP, and the Hoechst dye, 
respectively (scale bars, 10 µm and 3 µm for the magnified image). (b) The tau-positive signal inside FGF2-
GFP cells was quantified through an image-based analysis (3 independent biological replicates with at least 400 
processed cells per case). The data represent mean values ± s.d. and were statistically analysed through one-way 
ANOVA followed by Tukey’s post hoc analysis. (c)  CHOK1 RD-GFP cells were co-cultured with  CHOK1 tau 
E14,  CHO745 tau E14, and  CHOK1 tau E14 C291/322A cells. All combinations were stained with tau10 and GFP 
antibodies for full-length tau and RD-GFP detection, respectively. Hoechst dye was used for nuclear staining. 
Scale bars correspond to 15 µm and 5 µm for the original and magnified images, respectively. (d) The RD-GFP 
positive inclusions were quantified through a semi-automated image analysis of randomly selected z-projected 
scans and the number of inclusions/cell for each condition was compared to the  CHOK1 tau E14-CHOK1 
RD-GFP co-culture combination (3 independent biological replicates with at least 330 processed cells per case). 
The data represent mean values ± SEM and were statistically analysed through one-way ANOVA followed by 
Tukey’s post hoc analysis.
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 systems62, our quantitative analysis of the retinal damage at the Drosophila melanogaster eye combined with the 
biochemical characterization of the expressed tau species suggest that the phosphomimetic-induced aggregation 
of tau E14 substantially contributes to the resulted toxicity. Moreover, our lab as well as others have previously 
demonstrated that the trans-cellular propagation of misfolded proteinaceous species can be effectively modelled 
in the fruit fly brain and such events significantly influence the lifespan of these  animals63,64. As hyperphospho-
rylation increases the secretion propensity and thereby the cell-to-cell spreading efficiency of  tau16, we cannot 
rule out the occurrence of such phenomena that could further enhance the toxicity in the retinal cells should be.
We further addressed the specificity of tau secretion and the mechanistic details governing this process in a 
Drosophila neuronal cell culture system. Although the elevated extracellular CSF-tau levels are often attributed to 
the passive release of the protein due to neurodegeneration, the endogenous or the ectopic expression of human 
tau has not been associated to toxic phenotypes in cultured  cells65. Similarly, in our study we observe similar 
levels of cell death between control and tau-overexpressing cells. Notably, even though tau E14 was the only tau 
variant detected in the conditioned medium, there was no apparent difference in toxicity or protein expression 
levels among the cells expressing the different tau variants, thereby indicating the occurrence of active secre-
tion mechanisms driven by tau phosphorylation. This is further supported by the dependence of tau secretion 
on temperature changes as a marker of cellular mechanisms mediating the process. On this aspect, we have 
previously demonstrated that tau is able to interact with components of the plasma membrane in the absence 
of  ATP16, a feature also commonly shared among several Type I UPS  members30,55. Therefore, we envision that 
while the interaction of tau with lipid components occurs independently of ATP, the steps prior and after these 
events could energetically rely on cellular functions. However, since the cell line employed in this study is derived 
from an early developmental stage in the lifespan of the fruit  fly44 and tau secretion has been shown to rely on 
neuronal activity in mammalian  cultures66, a subject of future studies should be to address these phenotypes in 
differentiated neuronal  cells67 or in Drosophila melanogaster-derived primary neuronal  populations68.
We have previously shown that the PI(4,5)P2 represent one of the lipid components that mediate the trans-
location process of tau across the plasma  membrane16. This has been corroborated by further findings linking 
the secretion of tau with cholesterol and sphingomyelin  levels17, collectively identifying these three plasma 
membrane molecules as significant trans-elements governing the unconventional secretion of tau. Indeed, when 
we directed tau away from the plasma membrane to the nuclear compartments, the secretion of the protein was 
vastly reduced. Surprisingly though, the artificial localization of tau to the plasma membrane through lipid-based 
targeting  motifs51 was equally detrimental for the extracellular levels of tau. Interestingly, this is in line with 
our previous results from the liposome membrane integrity assay, where the replacement of the PI(4,5)P2 with 
Ni–NTA lipids led to a complete abolishment of the membrane activity, despite the recruitment of tau due to its 
N-terminal His-tag16. This suggests that the tau-PI(4,5)P2 interaction is required over other forms of membrane 
recruitment and it further hints towards the existence of dedicated regions within the tau sequence that may be 
responsible for the efficient translocation. For FGF2 and HIV-Tat the interaction with the PI(4,5)P2 is mediated 
by highly positively-charged residues within their amino acid  sequence29,69. The tau isoform used throughout 
this study contains 66 positively charged residues, of which 28 are located within the MTBR. Intriguingly, the 
disease-associated hyperphosphorylation of tau occurs predominantly in epitopes outside the repeat domain, 
while leaving these positively charged moieties largely  unaffected16,70,71. Moreover, a recent study identified the 
lysine residues within the repeat domains as the primary binding sites to the surface receptor LRP1 en route to 
the internalization of tau from  neurons72. This suggests that the MTBR of tau can act as an interaction surface 
for molecules other than the microtubules. Whether this, or other regions of the protein permit the interaction 
with negatively charged PI(4,5)P2 at the inner plasma membrane leaflet remains unknown.
Finally, our work addressed the contribution of the two cysteines (C291 and C322) on the secretion and the 
trans-cellular spreading of tau. The first cysteine residue is located at the second repeat of the MTBR and there-
fore it is present only in tau isoforms containing 4 repeat domains, while the second cysteine can be found in 
all  isoforms36. These epitopes have been primarily linked to the formation of intra- or inter-molecular disulfide 
bridges between tau molecules, with the latter being of great interest as a potential initiating step for the formation 
of tau  amyloids37,73. Mutation of the first cysteine residue into alanine that allows only the formation of intermo-
lecular disulfide bridges, led to an approximately 50% reduction of secreted tau levels in two independent cell 
culture systems. Interestingly though, the complete prevention of both intra- and intermolecular disulfide bonds 
by converting both cysteines into  alanine74 did not further impair tau secretion. Additionally, in accordance to 
our previous observations regarding the impact of tau secretion on the trans-cellular  propagation16, this reduction 
was also corroborated by decreased cell-to-cell spreading efficiency as well as lower levels of aggregation in our 
biosensor cell line. We envision that the cysteine-dependent secretion phenotype relies on the formation of intra-
molecular disulfide bonds, which would in turn provide a tighter folding of the tau molecules into temporary and 
dynamic structures that allow the completion of the translocation  process75,76. Notably, this mechanism would 
distinguish tau from the pathway by which FGF2 is  secreted24, where the cysteine-dependent oligomerization is 
a critical determinant that drives the translocation  process35. However, as the secretion potency of the cysteine 
mutant versions of tau was not fully depleted, we cannot rule out the contribution of other cis-elements on the 
tau sequence mediating this process and could potentially foster the formation of cysteine-independent oligo-
meric  assemblies74 that are able to translocate to the extracellular space. Furthermore, a limitation of our studies 
is the employment of a single tau isoform and future work should systematically determine the contribution of 
the second repeat domain in the MTBR as well as the N-terminal projection domains, especially since the latter 
have been directly associated to interact with the plasma  membrane77.
Collectively, the herein described findings further advance our understanding on the mechanistic details 
governing the Type I unconventional secretion of tau. We propose that specific residues within the tau sequence 
mediate the interaction with the inner plasma membrane leaflet. Notably, we demonstrate that the two cysteine 
residues of full-length tau act as key mediators of this phenotype, thereby identifying a novel cis-element 
11
Vol.:(0123456789)
Scientific Reports |        (2021) 11:12946  | https://doi.org/10.1038/s41598-021-92433-3
www.nature.com/scientificreports/
governing the unconventional secretion of tau. Therefore, we suggest that the disease-associated redox distur-
bances in physiological cellular homeostasis might not only be a source of neuronal  damage78, but they could 
in turn drive and promote the trans-cellular propagation of tau. Most importantly, such efforts for the in-depth 
characterization of the molecular mechanisms involved in the initiation and progression of the disease-related 
pathology will provide a stepping stone in the design of therapeutic approaches against neurodegeneration.
Methods
All chemicals and culture media were purchased by Sigma-Aldrich, unless otherwise mentioned. The statistical 
analyses shown in the study were performed using the GraphPad Prism software (GraphPad Software) with the 
following significances: nsp > 0.05; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; and ****p ≤ 0.0001.
Drosophila melanogaster transgenic lines and husbandry. All flies were raised on standard corn-
meal and molasses medium. Crosses were kept for three days at 25 °C before shifting them to 29 °C. The prog-
enies were collected within a window of 24 h and mated female flies were kept at 29 °C. All flies were age matched 
when used for experiments. The expression of all constructs at the retinal cells was achieved using the X-GMR-
Gal4 driver line, which we acquired from the Bloomington Drosophila Stock Center (FlyBase ID: FBti0072862). 
The tau lines were kindly provided by the M. Feany lab (UAS-tau  wt38 FlyBase ID: FBtp0014839, UAS-tau  E1441 
FlyBase ID: FBtp0055829, UAS-tau  AP40 FlyBase ID: FBtp0055953). The UAS-eGFP line was acquired from the 
Bloomington Drosophila Stock Center (FlyBase ID: FBti0013988).
Toxicity assay at the Drosophila eyes. The Drosophila melanogaster flies expressing the tau variants or 
GFP were moved to 29 °C after eclosion and analysed at 2 or 3 days of age. For image acquisition, the flies were 
initially anesthetized with  CO2 and gently laid on a drop of nail polish to immobilize them. The Drosophila heads 
were photographed using a Zeiss STEMI 2000-C binocular epifluorescence microscope and Axiocam camera. 
The severity of the roughness at the fly eye was quantified using the ImageJ open-source plugin Flynotyper79 and 
all values were finally compared to the GFP control line.
Sarkosyl‑insoluble proteins isolation. For the in  vivo sarkosyl-insoluble fractions, 6 mated flies per 
genotype were fresh-frozen in liquid nitrogen and decapitated. The frozen heads were homogenized in 6.7 µl/
head ice-cold Buffer A (50 mM Tris–HCl pH 7.5, 2 mM  Na3VO4, 50 mM NaF, 50 mM β-Glycerophosphate, 
150  mM NaCl, 2  mM  MgCl2, 1 × cOmplete EDTA-Free protease inhibitors mix, 1 × PhosSTOP phosphatase 
inhibitors mix) for 45 s on maximum speed using a Minilys homogenizer (Bertin Instruments). The homogen-
ate was centrifuged at 6000g for 5 min at 4 °C and 34 µl of clarified homogenate was isolated. The homogeniza-
tion process was repeated using an equal amount of Buffer A and 34 µl of clarified homogenate were combined 
with the first round, while the pellet was discarded. Subsequently N-lauroylsarcosine, Triton X-100, and SDS 
were added to final concentrations of 1% w/v, 1% w/v, and 0.1% w/v, respectively (Sarkosyl-Lysis Buffer). Upon 
the final addition of β-MeOH to 0.1 M final concentration (1% v/v), the samples were shortly vortexed and 
incubated at 37 °C for 1 h under 700 rpm orbital shaking. Then, the samples were centrifuged at 4 °C for 30 min 
at 21,000g. The supernatant corresponding to the soluble proteins was isolated and mixed with Lämmli, while 
the pellet was resuspended with an equal volume of Buffer A and the centrifugation step was repeated. This 
wash-supernatant was discarded and the pellet was resuspended in 50 µl Lämmli. Both fractions were boiled for 
10 min at 95 °C and analysed in SDS-PAGE and western blotting.
The Drosophila neuronal BG2-c6 cells were cultured in 24-well plates for 48 or 72 h upon  Cu2+ induction and 
were initially rinsed with PBS and before gently detached by resuspension in PBS. The cells were shortly pelleted 
(5000g, 5 min, 4 °C) and then lysed for 30 min on ice with Sarkosyl-Lysis Buffer. The lysate was centrifuged at 
21,000g for 30 min at 4 °C and the supernatant (soluble fraction) was separated and mixed with Lämmli. The 
pellet was washed with 50 µl Sarkosyl-Lysis Buffer, centrifuged again and resuspended in Lämmli. Both soluble 
and insoluble fractions were boiled at 95 °C for 10 min before SDS-PAGE and western blotting analysis.
Genomic DNA isolation from tau transgenic Drosophila melanogaster flies. Two flies from each 
genotype were shortly anesthetized with  CO2 and transferred into a tube on ice. The flies were squished using 
a pipette tip in 50 μl of Genomic DNA Extraction Buffer (10 mM Tris–HCl pH  8, 1 mM EDTA, 25 mM NaCl, 
supplemented immediately before use with 200 μg/ml Proteinase K). The reaction was incubated for 30 min at 
37 °C and subsequently boiled at 95 °C for 2 min to inactivate the Proteinase K. From this mixture 1–2 μl were 
used in a PCR for amplifying the tau coding sequences.
Cell lines maintenance. Drosophila melanogaster neuronal BG2-c6 cells (ML-DmBG2-c6) were obtained 
from the Drosophila Genomics Resource Center (DGRC) and were maintained in Schneider’s Drosophila 
medium (Thermo Fisher Scientific), supplemented with 10% FBS, 100 IU/ml penicillin, and 100 µg/ml strep-
tomycin, and 10 µg/ml insulin at 25 °C, and atmospheric conditions. Chinese Hamster Ovarian (CHO) cells 
were maintained in α-modified Minimum Essential Medium (MEM-a), supplemented with 10% fetal calf serum 
(FCS, Biochrom AG), 2 mM glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin at 37 °C, 5%  CO2 
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and 95% humidity. Human Embryonic Kidney (HEK) EcoPack 2–293 cells were maintained in collagen-coated 
(Collagen R, Serva Electrophoresis) plates with Dulbecco’s modified Eagle Medium (DMEM, Sigma-Aldrich), 
supplemented with 10% FCS, 100  IU/ml penicillin, and 100 µg/ml streptomycin at 37  °C, 5%  CO2 and 95% 
humidity. Sf9 cells were grown in roller culture bottles in Sf-900 II serum-free medium (Thermo Fisher Scien-
tific) at 27 °C under shaking at atmospheric conditions.
Stable cell lines generation. CHOK1 cells stably expressing the tau E14 C291A and tau E14 C291/322A 
variants were generated as described  previously16. Briefly, as target cells the genetically modified  CHOK1 cell line 
was  employed80, which expresses the murine cationic amino acid transporter MCAT-181 and the doxycycline-
sensitive transactivator rtTA2-M282. For retrovirus production, the MBS Mammalian Transfection Kit (Agilent 
Technologies) was used on EcoPack 2–293 cells according to manufacturer’s instructions. The day before trans-
fection, the cells were seeded in collagen-coated 10 cm dishes in such density that the next day they would reach 
80% confluency. The cells were transfected with 9 µg retroviral plasmid containing the gene of interest and after 
production of the viruses, they were delivered to the  CHOK1 target cells according to manufacturer’s instruc-
tions, adapting the recommended volumes as needed. Upon viral transduction, the target cells were selected by 
400 µg/ml Hygromycin B for approximately 2–3 weeks. The  CHOK1 FGF2 wt-GFP,  CHOK1 tau E14,  CHO745 tau 
E14, and the  CHOK1 RD-GFP cell lines were previously  generated16,32. Expression of the desired proteins in the 
stable CHO cells was induced by addition of doxycycline into the medium to a final concentration of 1 µg/ml.
Plasmids and primers. The transient transfections of the BG2-c6 cells were performed using the pMT-
puro vector (Addgene plasmid #17923). The coding sequences of the tau variants were subcloned using the fol-
lowing pair of primers: tau_KpnI_fwd (TAG CTG GTA CCT ACC AAT CAA ATG GCT GAG CCC CGC CAG GAG 
) and tau_3xHA_NotI_rev (CTG AGC GGC CGC TTA TTA AGC GTA ATC TGG AAC ATC GTA TGG GTA AGC 
GTA ATC TGG AAC ATC GTA TGG GTA AGC GTA ATC TGG AAC ATC GTA TGG GTA CAA ACC CTG CTT GGC 
CAGGG). The single-cysteine mutant version of the tau E14 variant (tau E14 C291A) was generated by replac-
ing the cysteine residue at position 291 and the double-cysteine variant (tau E14 C291/322A) by converting 
both epitopes at positions 291 and 322 (numbering is based on the longest tau 2N4R isoform) into alanines 
through site-directed mutagenesis using the following pairs of primers: tau C291A_sense (tagcaacgtccagtc-
caaggctggctcaaaggataatatc), tau C291A_antisense (gatattatcctttgagccagccttggactggacgttgcta), tau C322A_sense 
(gcaaggtgacctccaaggctggctcattaggcaaca), and tau C322A_antisense (tgttgcctaatgagccagccttggaggtcaccttgc). The 
tau E14 cysteine mutant variants were then subcloned into the pMT-puro vector using the aforementioned 
tau_KpnI_fwd and tau_3xHA_NotI_rev primers, while for the stable cell lines generation, the coding sequences 
were subcloned into the pRTi-TRE2  vector16 with the following pair of primers: tau_pRTi_BamHI_fw (TAG 
CTG GAT CCT ACG CCA CCA TGG CTG AGC CCC GCC AGGAG) and tau 3xHA_pRTi_PacI_rev (CTG ATT AAT 
TAA TTA TTA AGC GTA ATC TGG AAC ATC GTA TGG GTA AGC GTA ATC TGG AAC ATC GTA TGG GTA AGC 
GTA ATC TGG AAC ATC GTA TGG GTA CAA ACC CTG CTT GGC CAGGG). The pCMV6-myc-TPPP plasmid 
(Origene plasmid #RC213142) was used to amplify the coding sequence of TPPP, which was subcloned to the 
pMT-puro vector using the following set of primers: TPPP_KpnI_fw (TAG CTG GTA CCT ACC AAT CAA ATG 
GCC GAT AAG GCC AAGC) and TPPP_3xHA_NotI_end_rev (CTG AGC GGC CGC TTA TTA AGC GTA ATC 
TGG AAC ATC GTA TGG GTA AGC GTA ATC TGG AAC ATC GTA TGG GTA AGC GTA ATC TGG AAC ATC GTA 
TGG GTA CTT GCC GCC CTG CAC C). The pMT-HA-Tsp96F was a kind gift from Michael  Boutros48 and was 
used to amplify the coding sequence of Tsp96F with the following pair of primers: Tsp97_KpnI_fw (TAG CTG 
GTA CCT ACC AAT CAA ATG ggtctcaacggctgctgttcg) and Tsp97_3xHA_NotI_rev (CTG AGC GGC CGC TTA TTA 
AGC GTA ATC TGG AAC ATC GTA TGG GTA AGC GTA ATC TGG AAC ATC GTA TGG GTA AGC GTA ATC TGG 
AAC ATC GTA TGG GTAggccttgtagtgctgattcct). The cellular localization signals to generate the chimeric tau 
E14 variants were introduced by amplifying the tau E14 cDNA with the aforementioned tau_3xHA_NotI_rev 
primer and the following forward primers: tau_LCP1_SP_fw (TAG CTG GTA CCT ACC AAT CAA ATG TTC AAG 
TTC GTG ATG ATC TGC GCC GTG CTG GGC CTG GCC GTG GCC GCT GAG CCC CGC CAG GAG), tau_NLS_
KpnI_fwd (TAG CTG GTA CCC AAT CAA ATG CGC AGC CGC GCC GAT CCC AAG AAG AAG CGC AAG GTG 
GAT CCC AAG AAG AAG CGC AAG GTG GAG CCC AAG AAG AAG CGC AAG GCT GAG CCC CGC CAG GAG ), 
and tau_Lck_KpnI_fwd (TAG CTG GTA CCT ACC AAT CAA ATG GGC TGC GGC TGC AGC AGC CAC CCC GAG 
GCT GAG CCC CGC CAG GAG). The tau E14 kRas construct was generated by using the following set of primers: 
tau_3xHA_KpnI_fwd (TAG CTG GTA CCT ACC AAT CAA ATG TAC CCA TAC GAT GTT CCA GAT TAC GCT TAC 
CCA TAC GAT GTT CCA GAT TAC GCT TAC CCA TAC GAT GTT CCA GAT TAC GCT GCT GAG CCC CGC CAG ) 
and tau_K-Ras4B_NotI_rev (CTG AGC GGC CGC TTA TTA CAT CAC GGT GCA GCG GGT GCG GCT CTT CTT 
CTT CTT CTT CTT GCC ATC CTT GCT CAA ACC CTG CTT GGC CAG GG).
Transient transfections. The BG2-c6 cells were transiently transfected using the Effectene Transfection 
Reagent (Qiagen) according to the manufacturer’s instructions. Briefly, confluent cells were detached by gentle 
tapping and resuspension. For one well of a 24-well plate, 100 ng of plasmid were diluted in Buffer EC and 1.6 µl 
of the Enhancer was added. The mixture was vortexed and incubated at RT for 5 min. Subsequently, 5 µl of the 
Effectene Transfection Reagent was added and the solution was vortexed for 10 s. The reaction was incubated for 
10 min at RT and complete medium was added up to 350 µl. The complexes were mixed with an equal volume 
of cells at a final concentration of 1.5  106 cells/ml and they were plated on concanavalin A (ConA, 0.5 mg/ml)-
coated plates. After 6 h, the complexes were removed and replaced with fresh medium containing 1 mM  CuSO4 
for expression induction (unless indicated otherwise for titration experiments). For immunofluorescence (IF) 
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Antibodies. 
Antibody Source WB IF
Rabbit polyclonal anti-HA Sigma-Aldrich 1:1000 1:500
Mouse monoclonal alpha-tubulin Developmental StudiesHybridoma Bank – 1:200
Rabbit polyclonal anti-actin Sigma-Aldrich 1:3000 –
Rabbit polyclonal anti-Glyoxalase 1 Santa Cruz Biotechnology 1:3000 –
Chicken polyclonal anti-GFP Aves Labs Inc 1:1000 1:300
Mouse monoclonal tau A-10 Santa Cruz Biotechnology – 1:200
Mouse monoclonal anti-HSPGs 10E4 Biomol 1:100
Mouse monoclonal anti-GAPDH Thermo Fisher Scientific 1:15000 –
Rabbit polyclonal anti-tau KJ9A Agilent Technologies/Dako 1:5000 –
Alexa Fluor goat anti-Rabbit 488 Thermo Fisher Scientific – 1:1000
Alexa Fluor goat anti-Rabbit 546 Thermo Fisher Scientific – 1:1000
Alexa Fluor goat anti-Mouse 546 Thermo Fisher Scientific – 1:1000
Alexa Fluor goat anti-Chicken 488 Thermo Fisher Scientific – 1:1000
Alexa Fluor goat anti-Mouse 680 Thermo Fisher Scientific 1:5000 –
IRDye 800CW goat anti-Rabbit LI-COR Biosciences 1:5000 –
HRP-conjugated goat anti-Rabbit Thermo Fisher Scientific 1:2000 –
HRP-conjugated goat anti-Mouse Thermo Fisher Scientific 1:2000 –
HRP-conjugated goat anti-Chicken Thermo Fisher Scientific 1:2000 –
In vitro dephosphorylation. BG2-c6 cells were transfected and after the indicated expression time points 
were rinsed once with PBS and then detached by gentle resuspension with PBS. The cells from 2 wells were 
mixed and divided in two equal parts before pelleting (1000g, 10 min, 4 °C). Subsequently, they were lysed with 
either PPase-lysis buffer (25 mM HEPES pH 7.4, 300 mM NaCl, 10% Glycerol, 1 × EDTA-Free Protease Inhibitor 
mix, 1% w/v NP-40) or Lysis Buffer (25 mM HEPES pH 7.4, 300 mM NaCl, 10% Glycerol, 10 mM EGTA, 50 mM 
NaF, 2 mM  Na3VO4, 50 mM β-Glycerophosphate, 1 × EDTA-Free Protease Inhibitor mix, 1 × Phosphatase Inhib-
itor mix, 1% w/v NP-40) and incubated at 4 °C for 30 min. The lysates were clarified by centrifugation (14,000g, 
15 min, 4 °C) and incubated with Antarctic Phosphatase for 1 h at 37 °C. The reactions were stopped by the 
addition of Lämmli buffer and boiling at 95 °C for 10 min.
Isolation of secreted proteins in the medium. The conditioned medium was clarified through a series 
of centrifugation steps (all at 4 °C) to isolate the free  proteins83: 300g, 10 min with the pellet corresponding to liv-
ing floating cells; 2000g, 10 min with the pellet corresponding to dead cells; 10,000g, 30 min with the pellet cor-
responding to cell debris; 21,000g 30 min with the pellet corresponding to insoluble proteins. For exosomes iso-
lation, the medium after the last clarification step was subjected to ultracentrifugation (100,000g, 70 min, 4 °C). 
Both insoluble and exosomal fractions were washed once with PBS and re-pelleted with the same conditions 
before resuspension in Lämmli and boiling for 10 min at 95 °C. Equal volumes of the supernatant fractions cor-
responding to the clarified medium were subjected to immunoprecipitation using the KJ9A pan-tau antibody.
The day before harvesting the medium, the pan-tau antibody was coupled to Dynabeads Protein G. For this 
purpose, 30 µl of properly mixed beads for each reaction were mixed with 5 µg of polyclonal anti-tau antibody 
diluted in 200 µl PBS-T. The antibody-beads mixture was incubated with rotation overnight at 4 °C. The next 
day, the Dynabeads were magnetically separated from the solution and the supernatant was discarded. The 
antibody-coupled beads were initially washed twice with 200 µl per reaction of PBS-T and then twice with 250 µl 
of Conjugation Buffer (20 mM  Na2HPO4, 150 mM NaCl, pH 7–9). The equilibrated antibody-coupled beads 
were incubated while rotating for 2 h at RT with freshly prepared 5 mM of  BS3 (bis(sulfosuccinimidyl)suberate) 
cross-linker, diluted in Conjugation Buffer. At the end of the incubation, the reaction was quenched by addition of 
12.5 µl Quenching Buffer (1 M Tris–HCl pH 7.5) per reaction and incubated for 30 min with rotation. The beads 
were subsequently washed three times with 200 µl PBS-T per reaction and finally resuspended with the clarified 
conditioned medium. The immunoprecipitation was performed overnight at 4 °C with constant rotation. The 
next day, the beads were washed three times with 200 µl PBS-T and transferred to a new tube before the elution. 
The immunoprecipitated proteins were eluted by addition of 30 µl of IP Elution Buffer (25 mM Citrate pH 2.4) 
and incubation for 10 min at RT while rotating. At the eluted fraction 7.5 µl of IP Neutralization Buffer (0.5 M 
Tris–HCl pH 8.3) and 7.5 µl of 4 × Lämmli sample buffer were added (final volume 45 µl) and the mixture was 
boiled for 10 min at 95 °C. After subjecting the secreted tau to western blotting, they were densitometrically 
quantified and normalized to the intracellular expression levels, which was defined as the ratio between tau 
and loading control (actin or Glo1 for BG2-c6 and GAPDH for  CHOK1 cells) in the lysate fractions. Finally, the 
normalized secreted tau levels were compared to the corresponding reference condition for each experiment 
and plotted accordingly for statistical analysis.
Cell‑surface biotinylation. Approximately 250,000  CHOK1 cells (0.8 ×  105 cells/ml) were seeded in 6-well 
plates and induced with 1 µg/ml doxycycline. After 48 h of expression, the cells were transferred on ice, the 
14
Vol:.(1234567890)
Scientific Reports |        (2021) 11:12946  | https://doi.org/10.1038/s41598-021-92433-3
www.nature.com/scientificreports/
medium was quickly removed and the cells were rinsed twice with 1 ml PBS Ca/Mg (PBS, 1 mM  MgCl2, 0.1 mM 
 CaCl2). Afterwards they were incubated with 600 µl of 1 mg/ml EZ-Link Sulfo-NHS-SS-Biotin diluted in Bioti-
nylation Incubation Buffer (150 mM NaCl, 10 mM Triethanolamin, 2 mM  CaCl2, final pH ≥ 9.0) for 30 min on 
ice while mildly shaking. At the end of the incubation the biotin solution was removed, the cells were rinsed 
once with 500 µl Biotinylation Quenching Buffer (PBS Ca/Mg, 100 mM Glycine) and then incubated with 600 µl 
Biotinylation Quenching Buffer on ice for 20 min with mild shaking. Then, the cells were rinsed twice with PBS 
and lysed with 300 µl Biotinylation Lysis Buffer (50 mM Tris–HCl pH 7.5, 62.5 mM EDTA pH 8.0, 0.4% w/v 
Deoxycholate, 1% w/v NP-40, EDTA-Free Protease Inhibitor mix) for 10 min at 37 °C. The cells were scraped and 
the lysate was transferred to a tube. After a 3 min sonication step, the lysate was incubated at RT for 15 min with 
vortexing every 5 min to solubilize all proteins. This was followed by a centrifugation step at 18,000 g for 10 min 
at 4 °C and the pellet was discarded. 15 µl from the clarified lysate were mixed with 15 µl of 4 × Lämmli (input of 
total cell lysate) and boiled for 10 min at 95 °C. For every reaction 40 µl suspension (or 20 µl packed) Streptavidin 
UltraLink Resin beads were employed, which were pelleted by centrifugation at 3,000 g after every washing and 
incubation step. The beads were washed 3 times with 300 µl of Biotinylation Lysis Buffer and then incubated for 
1 h at RT with the clarified cell lysate. Afterwards they were washed once with 500 µl of Biotinylation Washing 
Buffer 1 (50 mM Tris–HCl pH 7.5, 62.5 mM EDTA pH 8.0, 500 mM NaCl, 0.4% w/v Deoxycholate, 1% w/v 
NP-40, 1 × EDTA-Free Protease Inhibitor mix) and three times with 500 µl of Biotinylation Washing Buffer 2 
(50 mM Tris–HCl pH 7.5, 62.5 mM EDTA pH 8.0, 500 mM NaCl, 0.4% w/v Deoxycholate, 0.1% w/v NP-40, 
1 × EDTA-Free Protease Inhibitor mix). The washed beads at the end were eluted by adding 40 µl 4 × Lämmli 
buffer and boiling for 10 min at 95 °C (surface fraction). For the SDS-PAGE analysis, 1.6% of the total cell lysate 
(10 µl) and 30% of the surface biotinylated fraction (20 µl) were loaded. At the downstream analysis, all samples 
with biotinylated GAPDH more than 0.5% were excluded.
Treatment of cells with inhibitors. After 66 h of expression the medium was removed, the cells were 
rinsed once with PBS and new medium was added containing 1 mM  CuSO4 and 33 µM Brefeldin A or 50 µM 
Monensin. The cells were incubated for 6 h in the presence of the inhibitors and then the medium was collected, 
clarified and subjected to immunoprecipitation, while the cells were lysed in Lysis Buffer. The lysate was clarified 
(14,000g, 15 min, 4 °C) and mixed with Lämmli buffer, followed by a boiling step at 95 °C.
For the  NaClO3 treatment, a pre-treatment step before induction of expression was performed to ensure 
low sulfated proteoglycans levels at the cell surface throughout the experiment. BG2-c6 cells were transfected 
as described above and after 6 h the complexes were removed and replaced with fresh medium containing the 
indicated concentrations of  NaClO3. After 2 days, the cells were detached by gently tapping and resuspension, 
counted, and seeded in new ConA-coated plates with 1 mM CuSO4 and the corresponding  NaClO3 for further 
72 h. Afterwards the medium was collected and the surface-retained tau population was retrieved by Heparin-
wash. Both fractions were clarified and subjected to immunoprecipitation, while the cells were lysed with Lysis 
Buffer.
Purification of recombinant tau E14. The recombinant 6xHis-tau E14 was expressed and purified from 
Sf9 insect cells using the Baculovirus expression system as previously  described16,84. Briefly, the cells from two 
500 ml cultures were combined, pelleted, and lysed with Purification Lysis Buffer (Lysis Buffer plus 1 mM Ben-
zamidine, 1 mM PMSF, 14 mM 2-mercaptoethanol) by vigorous pipetting, followed by snap-freezing in liquid 
nitrogen. The frozen lysate was quickly thawed, sonicated using a Sonifier cell disruptor B-30 (Branson Sonic 
Power) and boiled for 10 min at 95 °C. The lysates were centrifuged (100,000g, 1 h, 4 °C) and the supernatant 
was loaded on a  Ni2+ affinity column (HisTrap FF, GE Healthcare Life Sciences), The purified protein was con-
centrated using 10 kDa cutoff Amicon Ultra-4 concentrators and loaded on a Superdex 200 10/300 GL (GE 
Healthcare Life Sciences) size exclusion chromatography column with HK Buffer (25 mM HEPES–KOH pH 7.4, 
100 mM KCl, freshly supplemented with 1 mM DTT) as buffer exchange. The fractions were analysed for purity 
and quality through SDS-PAGE and total protein staining with Coomassie InstantBlue. The affinity purification 
and size exclusion chromatography steps were performed using the ÄKTA system.
In vitro recombinant tau aggregation. Recombinant tau E14 was mixed with freshly prepared Heparin 
in final concentrations of 15 µM and 3.75 µM (tau:Heparin 4:1). The protein was left to aggregated at 37 °C under 
constant shaking for 72 h in the presence of Protease inhibitors and 2 mM DTT. The generation of recombinant 
filaments at the end of the incubation was validated by SDS-PAGE and Thioflavin T analysis. The tau E14 fibrils 
were sonicated in water bath sonicator for 15 s, aliquoted and snap-frozen before storage at − 80 °C.
Transduction of CHO RD‑GFP cells with recombinant fibrils. The liposome-mediated transduction 
was conducted as described  previously16. Approximately 15,000 cells  CHOK1 RD-GFP cells were seeded in 8-well 
Lab-Tek chambers (Thermo Fisher Scientific) in the presence of 1 µg/ml doxycycline. The next day, for transduc-
ing 2 wells of an 8-well, 24 µl of Opti-MEM I Reduced Serum (Thermo Fisher Scientific) medium was supple-
mented with 1 µl of Lipofectamine-2000 and these were mixed with 25 µl Opti-MEM I Reduced Serum medium 
containing the sonicated tau fibrils. As control, monomeric tau E14 was employed. The protein-liposomes mix 
was incubated at RT for 20 min and then 20 µl for every well were applied drop-wise to the cells. The final con-
centration of tau fibrils or monomer applied to the cells was 400 nM. About 16 h later, the cells were fixed and 
processed for analysis.
Cytotoxicity determination by measuring the LDH activity. The cytotoxicity assessment was per-
formed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) according to the manufacturer’s 
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instructions with slight modifications. After transfection with the tau variants and the indicated treatments, 
the medium was collected and clarified. The cells were rinsed with PBS and then lysed in 180 µl of LDH Lysis 
Buffer (full Schneider’s medium supplemented with 1 × Lysis Solution, approximately 0.8% Triton X-100 final 
concentration) for 45 min at RT. In order to measure the maximum LDH activity, 10% from every lysate was 
used. Full Schneider’s medium was employed as negative control. In a 96-well flat clear bottom plate, 50 µl from 
every sample was pipetted and mixed with 50 µl of CytoTox 96 Reagent. Every sample was measured in technical 
triplicates. The reaction was incubated at RT for 30 min protected from light. At the end of the incubation, 50 µl 
of Stop Solution was added to each well and the absorbance was measured using a FLUOstar Omega plate reader 
with the wavelength set at 490 nm. The measurement from every sample was corrected by subtracting the back-
ground. The cell death levels were calculated as % of the maximum LDH activity derived from the lysed cells.
Heparin wash of cell surface bound proteins. After 72  h of expression the medium was collected, 
clarified and used for further analysis. The cells were rinsed once with PBS and then incubated for 10 min on 
ice mildly shaking with freshly prepared 500 µg/ml Heparin diluted in Schneider’s medium without FBS. The 
Heparin-retrieved fractions were subjected to immunoprecipitation and analysed as described above.
Immunofluorescence. For immunofluorescence experiments the transfected BG2-c6 cells were cultured 
on Con-A coated glass cover slips for 72 h and the CHO cells on 8-well Lab-Tek chambers (Thermo Fisher Sci-
entific) for 48 h. After these time points for both cases, the medium was removed, the cells were rinsed once with 
PBS and then fixed with ice-cold methanol for 10 min. Afterwards the cells were washed 3 times with PBS and 
blocked with IF-blocking buffer (5% FCS diluted in PBS) for 30 min. The cells were incubated with appropriate 
concentrations of primary and secondary antibodies, diluted in IF-blocking buffer, for 1 h respectively, followed 
by 3 times PBS wash steps for both cases. At the end of the secondary antibody incubation, the cells were stained 
for 10 min with 1 µg/ml Hoechst 33342. Images were taken with a 63 × objective using a Zeiss Cell Observer 
widefield microscope and a Zeiss LSM 880 confocal microscope.
The tau trans-cellular spreading and the induction of aggregation analyses were performed as described 
 before16. Briefly, for the tau trafficking image analysis the co-culturing combinations were fixed and stained 
as described above. The imaging acquisition was performed for 3 independent experimental sets and for each 
experiment 20 randomly selected fields were imaged. The areas were acquired as z-stacks from the top to the 
bottom of the cells and the image analysis was performed using the Fiji software with a macro developed at the 
DKFZ Light Microscopy Core Facility (Heidelberg, Germany). After maximal z-projection, the stacks were 
locally subtracted for background using the Rolling ball algorithm subtraction and maximum intensity was 
further used for cells segmentation and analysis. The cells were segmented based on nuclear and cytoplasmic 
staining using the Median filter and Find Maxima tools, with Segmented Particles above lower threshold option 
activated. Initially the images of nuclei alone were segmented using the same ImageJ tools and excluded from 
further analysis. The same was applied for the tau expressing cells. Finally, the tau positive signal localized in 
the cytoplasm of the FGF2-GFP positive cells was counted for each cell cytoplasm separately using the Analyze 
Particles tool. A minimum of 400 cells per condition was analyzed. Statistical analysis was performed by calcu-
lating the % of FGF2-GFP cells with tau signal in their cytoplasm.
For the biosensor seeding image analysis, the transduced RD-GFP cells or the different culture combinations 
were fixed with 4% PFA (Electron Microscopy Sciences) diluted in PBS for 10 min at RT in order to preserve the 
GFP fluorescence of the aggregates. After a 10 min permeabilization step with 0.1% w/v Triton X-100, the cells 
were stained as described above. The imaging acquisition was performed with at least 3 independent experimental 
sets of single or co-culture combinations and for each experiment 20 randomly selected fields were imaged. The 
areas were acquired as z-stacks from the top to the bottom of the cells and the image analysis was performed using 
the Fiji software with a macro developed at the DKFZ Light Microscopy Core Facility (Heidelberg, Germany). 
The z-stacks were z-projected and locally background subtracted using the Rolling ball algorithm. Maximum 
intensity was further used for cell segmentation and analysis. Based on nuclear and cytoplasmic staining the cells 
were segmented using the Median filter and Find Maxima tools, with activated the option of Segmented Particles 
above lower threshold. The images of nuclei were segmented using the same ImageJ tools and excluded from 
further analysis. The same was also applied for the tau expressing cells. Finally, in the remaining GFP-positive 
cells the RD-GFP aggregates were counted for each cell separately using the Analyze Particles tool. A minimum 
of 1000 cells per condition was analyzed. Statistical analysis was performed by calculating the % of RD-GFP 
aggregates containing cells.
SDS‑PAGE analysis and western blotting. The protein samples mixed with Lämmli buffer (40% 
v/v Glycerol, 240 mM Tris–HCl pH 6.8, 8% w/v SDS, 0.04% Bromophenol Blue, 5% v/v 2-mercaptoethanol) 
were boiled at 95 °C for 10 min before loading. For regular SDS-PAGE analysis, 4–12% NuPAGE gradient gels 
(Thermo Fisher Scientific) were employed and run in NuPAGE MOPS SDS Running Buffer (Thermo Fisher Sci-
entific) for 55 min at 200 V. For the dephosphorylation and the MassSpec experiments, self-casted 10% or 15% 
acrylamide gels were used in order to obtain maximum resolution of the differentially phosphorylated tau bands. 
These gels were run in Towbin SDS-PAGE Running Buffer (25 mM Tris, 192 mM Glycine, 0.1% w/v SDS) until 
the dye front reached the end of the gel. The analyzed proteins were transferred to Immobilon FL PVDF mem-
branes (Millipore Corporation) and incubated for 1 h at RT with blocking buffer (5% w/v milk in PBS) under 
shaking. The membranes were washed 3 times with PBS-T and incubated overnight at 4 °C with the primary 
antibody diluted in Blot Incubation Buffer (1% w/v BSA diluted in PBS-T). The next day, the membranes were 
washed 3 times for 10 min with PBS-T and incubated for 1 h at RT with the secondary antibody diluted in Blot 
Incubation Buffer. All membranes (except the insoluble and medium fractions) were imaged using the LI-COR 
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Odyssey CLX Imaging System. The membranes with the insoluble and medium fractions were incubated with 
HRP-conjugated secondary antibodies diluted in Blot Incubation Buffer and were developed with Pico or Femto 
Chemiluminescent Substrate using the ImageQuant LAS 4000 system (GE Healthcare Life Sciences). All image 
analysis and quantifications were performed with the Image Studio Lite software.
In‑gel tryptic digestion and LC–MS/MS analysis. BG2-c6 cells were transiently transfected with 
the pMT-puro tau AP-3xHA plasmid in a 6-well plate using the Effectene Transfection Reagent (Qiagen) and 
according to the manufacturer’s instructions. Briefly, the cells were detached and for one well, 400 ng of plasmid 
were diluted in Buffer EC and 3.2 µl of the Enhancer was added. Subsequently, 10 µl of the Effectene Transfection 
Reagent was added, the reaction was incubated for 10 min at RT and complete medium was added up to 1000 µl. 
The complexes were mixed with an equal volume of cells at a final concentration of 1.5  106 cells/ml and they were 
plated on concanavalin A (ConA, 0.5 mg/ml)-coated plates. The complexes were replaced with fresh medium 
after 6 h and 3 days later the cells were expanded in T75 flasks. At this stage the expression of tau AP-3xHA was 
induced by adding 1 mM  CuSO4 for 3 days.
Subsequently, the cells were detached and lysed in Lysis Buffer for 30 min on ice. The lysate was clarified and 
subjected to immunoprecipitation using the Anti-HA Magnetic Beads (Thermo Fisher Scientific) according to 
the manufacturers’ instructions. The immunoprecipitated proteins were eluted with 30 µl of IP Elution Buffer and 
incubated for 10 min at RT while rotating. At the eluted fraction 7.5 µl of IP Neutralization Buffer) and 7.5 µl of 
4 × Lämmli sample buffer were added (final volume 45 µl) and the mixture was boiled for 10 min at 95 °C. The 
eluted fractions wetre analyzed by SDS-PAGE and stained with colloidal Quick Coomassie stain (Serva). The 
Coomassie stained bands were cut out and gel slices were transferred to a 96-well plate, automatically reduced, 
alkylated, and digested with  trypsin85. The peptides were isolated from the gel pieces with 50% acetonitrile/ 0.1% 
TFA, concentrated nearly to dryness in a SpeedVac vacuum centrifuge and diluted to a total volume of 30 µl 
with 0.1% TFA. 10 µl of the sample were analyzed by a Dionex UltiMate 3000RSLCnano HPLC system (Thermo 
Fisher Scientific) coupled either to a LTQ Orbitrap Elite or Q-Exactive-HF mass spectrometer (both Thermo 
Fisher Scientific). Samples analyzed on the LTQ Orbitrap Elite were loaded on a C18 trapping column (Acclaim 
PepMap100, C18, 5 µm, 300 µm i.d. × 5 mm, Thermo Fisher Scientific), using a loading buffer of 0.1% TFA at a 
flow rate of 30 µl/min. Peptides were eluted and separated on a C18 analytical column (Acclaim PepMap RSLC 
C18, 2 µm, 75 µm i.d. × 25 cm, Thermo Fisher Scientific) with a flow rate of 300 nl/min in a 50 min gradient 
from 96% MS Buffer A (1% acetonitrile, 0.1% formic acid) and 4% MS Buffer B (90% acetonitrile, 0.1% formic 
acid) to 60% MS Buffer A and 40% buffer B. One Orbitrap survey scan was followed by up to 20 data-dependent 
product ion scans in the LTQ ion trap. Samples analyzed on the Q-Exactive-HF system were directly injected 
to an analytical column (75 µm × 300 mm), which was self-packed with 3 µm Reprosil Pur-AQ C18 material 
(Dr. Maisch HPLC GmbH) and separated using a gradient from 97% MS Buffer A and 3% MS Buffer B to 40% 
MS Buffer A and 60% MS buffer B. MS data were acquired with an automatic switch between a full scan and up 
to 15 data-dependent MS/MS scans. To increase sensitivity for phosphorylated peptides of the target protein, 
inclusion lists consisting of m/z values for possible phosphorylated peptides were applied. The uninterpreted 
MS/MS spectra were searched against the target protein sequences, a reverse decoy version of these sequences 
and a common laboratory contaminant database, using the MaxQuant software with its built-in Andromeda 
search  algorithm86. The algorithm was set to use trypsin as proteolytic enzyme allowing up to two missed cleav-
ages, assuming carbamidomethylation as a fixed modification of cysteine, and oxidized methionine, acetylated 
N-termini and phosphorylation (serine, threonine, tyrosine) as variable modifications. All other parameters were 
set to default MaxQuant specifications. The false discovery rate (FDR), determined by searching the reverse data-
base, was set at 0.01 for both peptides and proteins. Modified peptides had additionally to exceed an andromeda 
score of 40 and a delta score of 6.
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